Dicerna Pharmaceuticals, Inc. (DRNA) At $11.69 Forms Top; Proteostasis Therapeutics (PTI) Shorts Decreased By 0.37%

June 28, 2018 - By Shannon Black

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Proteostasis Therapeutics Inc (NASDAQ:PTI) had a decrease of 0.37% in short interest. PTI’s SI was 3.18 million shares in June as released by FINRA. Its down 0.37% from 3.19 million shares previously. With 3.32M avg volume, 1 days are for Proteostasis Therapeutics Inc (NASDAQ:PTI)’s short sellers to cover PTI’s short positions. The SI to Proteostasis Therapeutics Inc’s float is 21.91%. The stock decreased 5.39% or $0.16 during the last trading session, reaching $2.81. About 463,972 shares traded. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has risen 10.56% since June 28, 2017 and is uptrending. It has underperformed by 2.01% the S&P500. Some Historical PTI News: 20/03/2018 – Sahm Adrangi’s Kerrisdale knifes Proteostasis’ ‘breakthrough’ cystic fibrosis data in a brutal biotech short attack $PTI -25%; 15/05/2018 – J Goldman & Co LP Exits Position in Proteostasis Therapeutics; 27/03/2018 – Consolidated Research: 2018 Summary Expectations for TE Connectivity, CNH Industrial N.V., Proteostasis Therapeutics, Qudian In; 17/04/2018 – Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation’s Therapeutic Development Network for the Study of the Company’s Amplifier, PTI-428, in CF Subjects on Background Symdeko™ Therapy; 21/03/2018 – Glancy Prongay & Murray LLP Announces Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors (PTI); 17/04/2018 – Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation’s Therapeutic Development Network for the Study of the Co; 23/04/2018 – PROTEOSTASIS THERAPEUTICS SAYS AMENDMENT EXTENDS RESEARCH TERM FOR INITIAL PROJECT UNDER ASTELLAS AGREEMENT TO DEC 4, 2018 – SEC FILING; 20/03/2018 – What happened to $PTI’s trial of PTI-428 with Kalydeco, which was supposed to read out this quarter? Why don’t they talk about it anymore? Why don’t they talk about the journal article that shows PTI-428 failing to increase protein levels or channel function? (4/5); 12/03/2018 – PTI: FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR PTI-428; 17/04/2018 – PROTEOSTASIS RECEIVES ENDORSEMENT FROM THE CYSTIC FIBROSIS FOUNDATION’S THERAPEUTIC DEVELOPMENT NETWORK FOR THE STUDY OF THE COMPANY’S AMPLIFIER, PTI-428, IN CF SUBJECTS ON BACKGROUND SYMDEKO™…

Dicerna Pharmaceuticals, Inc. (DRNA) formed multiple top with $12.74 target or 9.00% above today’s $11.69 share price. Dicerna Pharmaceuticals, Inc. (DRNA) has $617.48M valuation. The stock decreased 4.88% or $0.6 during the last trading session, reaching $11.69. About 605,865 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 317.27% since June 28, 2017 and is uptrending. It has outperformed by 304.70% the S&P500. Some Historical DRNA News: 20/04/2018 – DICERNA REPORTS SETTLEMENT OF ALL LITIGATION WITH ALNYLAM; 20/04/2018 – Alnylam: Dicerna to Be Restricted in Its Development of Certain Therapeutics for 18 Mos to Four Years; 17/04/2018 – STAT Plus: Trade secrets battle between Alnylam, Dicerna is just one of many; 17/05/2018 – Dicerna Pharmaceuticals, Inc; 20/04/2018 – DICERNA PHARMACEUTICALS – ALNYLAM WILL DISMISS ALL CLAIMS OF “TRADE SECRET MISAPPROPRIATION” & OTHER RELATED CLAIMS BROUGHT IN COURT AGAINST CO; 30/05/2018 – Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial; 17/05/2018 – Dicerna Treatment Granted Orphan Drug Status by FDA; 14/05/2018 – Dicerna Pharmaceuticals Believes It Has Sufficient Cash Through 2019, Assuming No New Fundin; 14/05/2018 – DICERNA PHARMACEUTICALS INC – BELIEVES THAT IT HAS SUFFICIENT CASH TO FUND EXECUTION OF ITS CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019; 20/04/2018 – DICERNA PHARMACEUTICALS INC – DICERNA WILL DISMISS ALL COUNTERCLAIMS ASSOCIATED WITH ALNYLAM’S TRADE SECRET MISAPPROPRIATION LITIGATION

Analysts await Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings on August, 9. They expect $-0.42 EPS, up 63.48% or $0.73 from last year’s $-1.15 per share. After $-0.30 actual EPS reported by Dicerna Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 40.00% negative EPS growth.

Investors sentiment decreased to 2.44 in Q1 2018. Its down 0.56, from 3 in 2017Q4. It fall, as 3 investors sold Dicerna Pharmaceuticals, Inc. shares while 13 reduced holdings. 24 funds opened positions while 15 raised stakes. 30.68 million shares or 5.45% more from 29.10 million shares in 2017Q4 were reported. Caxton stated it has 0.15% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Emerald Mutual Fund Advisers Trust owns 151,571 shares. Northern Trust holds 59,384 shares or 0% of its portfolio. Panagora Asset Mgmt accumulated 7,533 shares. Bluecrest holds 0.03% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 114,650 shares. Comml Bank Of Mellon reported 41,432 shares. Bogle Investment Lp De invested in 18,798 shares. State Street Corporation reported 22,583 shares. Goldman Sachs Grp holds 0% or 788,604 shares in its portfolio. First Manhattan Communication stated it has 0.02% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Susquehanna Interest Group Llp invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). California Employees Retirement invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Vanguard Group reported 1.23M shares. Quantitative Systematic Strategies Lc owns 11,794 shares or 0.02% of their US portfolio. 161,577 were accumulated by Geode Limited Liability Corporation.

Since March 19, 2018, it had 0 buys, and 4 sales for $425,035 activity. On Monday, March 19 Weissman James B sold $13,455 worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 1,035 shares. 9,669 Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares with value of $145,035 were sold by Brown Bob D.

Among 8 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Dicerna Pharmaceuticals has $17 highest and $10 lowest target. $11.83’s average target is 1.20% above currents $11.69 stock price. Dicerna Pharmaceuticals had 8 analyst reports since January 16, 2018 according to SRatingsIntel. SunTrust initiated the shares of DRNA in report on Monday, February 5 with “Buy” rating. The firm has “Buy” rating given on Friday, March 9 by Stifel Nicolaus. The stock has “Buy” rating by Cowen & Co on Wednesday, April 11. The firm has “Hold” rating given on Tuesday, March 27 by FBR Capital. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Hold” rating given on Friday, March 9 by Chardan Capital Markets. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Neutral” rating given on Friday, March 23 by H.C. Wainwright.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart